<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849184</url>
  </required_header>
  <id_info>
    <org_study_id>4305-063</org_study_id>
    <nct_id>NCT02849184</nct_id>
  </id_info>
  <brief_title>To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia</brief_title>
  <acronym>Super1</acronym>
  <official_title>A Multi-center, Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Suvorexant Versus Placebo on Sleep Pressure and Circadian Rhythm in Hypertensives With Insomnia: The Super 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jichi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satt Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jichi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of suvorexant versus
      placebo on sleep pressure and circadian rhythm in hypertensives with insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a 4-week run-in period and a 2-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sleep Systolic Blood Pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the efficacy of suvorexant versus placebo on sleep systolic blood pressure (SBP) by ambulatory blood pressure monitoring (ABPM).
Change: sleep SBP value at 2 weeks minus value at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Systolic Blood Pressure Variability</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the efficacy of suvorexant versus placebo on morning SBP variability by ABPM Variability: SD Change: value at 2 weeks minus value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Total Sleep Time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total sleep time was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Time to Sleep Onset</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time to sleep onset was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nighttime SBP in Patients Achieved High Sleep Satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2 weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Albumin-to-creatinine Ratio (UACR)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage change in UACR from baseline to 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nighttime SBP in Patients Achieved Low Sleep Satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage change in NT-proBNP from baseline to 2 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hypertension</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
    <arm_group_label>suvorexant</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily before bedtime.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [At interim registration]

        Patients who meet the following criteria are eligible for the study:

          1. Patients who give written consent of agreement to voluntarily participation in the
             clinical study

          2. Age 20 years or older

          3. Sex: Male or female

          4. Treatment classification: Outpatient

          5. Hypertensive patient who meet at least one of the following:

               -  Under antihypertensive medications

               -  Clinic systolic blood pressure (SBP) less than 160 mmHg

          6. Patients with insomnia who meet at least one of the following:

               -  Patients with any one of the following symptoms twice a week or more and at least
                  1 month-continuation: difficulty initiating sleep (time to sleep onset 2 hours or
                  more longer than usual), difficulty maintaining sleep (awakening twice or more in
                  the night), early morning awakening (awakening 2 hours or more earlier in the
                  morning than usual), difficulty sleeping deeply (no soundly asleep feeling at the
                  time of awakening in the morning).

                  b. Patients with interference with social or occupational function due to the
                  above insomnia symptoms

        [At official registration]

        Patients who meet the following criteria at the end of run-in period are eligible for the
        study:

          1. Stable unchanged antihypertensive medication for run-in period.

          2. Average morning home SBP more than 135 mmHg during 5 days before the end of run-in
             period.

        Exclusion Criteria:

          1. Patients with serious liver disease.

          2. Patients with serious respiratory disease.

          3. Patients with secondary hypertension

          4. Patients with sleep apnea syndrome

          5. Patients with history of narcolepsy or cataplexy

          6. Patients with history of organic cerebral disorders

          7. Patients with history of hypersensitivity to suvorexant

          8. Patients received CYP3A strongly-inhibitors including itraconazole, clarithromycin and
             ritonavir, saquinavir, nelfinavir, indinavir, telaprevir and voriconazole at the start
             of the run-in period

          9. Patients with average clinic SBP of 160 mmHg or more at the start of the run-in period

         10. Patients received suvorexant and other hypnotic at the start of the run-in period on a
             regular basis

         11. Patients who are breast-feeding, pregnant, possibly pregnant, or plan to become
             pregnant

         12. Patients who are considered not to be eligible for this study by their investigator or
             sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuomi Kario, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takahira Internal Medicine Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamasaki family clinic</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yagi hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <results_first_submitted>October 19, 2018</results_first_submitted>
  <results_first_submitted_qc>June 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>June 16, 2019</last_update_submitted>
  <last_update_submitted_qc>June 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jichi Medical University</investigator_affiliation>
    <investigator_full_name>Kazuomi Kario</investigator_full_name>
    <investigator_title>Professor &amp; Chairman, Division of Cardiovascular Medicine, Department of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02849184/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suvorexant</title>
          <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Suvorexant</title>
          <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="12.1"/>
                    <measurement group_id="B2" value="55.9" spread="9.5"/>
                    <measurement group_id="B3" value="56.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="4.4"/>
                    <measurement group_id="B2" value="25.9" spread="3.9"/>
                    <measurement group_id="B3" value="25.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nighttime systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.9" spread="15.9"/>
                    <measurement group_id="B2" value="140.7" spread="18.1"/>
                    <measurement group_id="B3" value="139.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nighttime diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.5" spread="8.7"/>
                    <measurement group_id="B2" value="84.2" spread="10.2"/>
                    <measurement group_id="B3" value="82.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Sleep Systolic Blood Pressure</title>
        <description>To compare the efficacy of suvorexant versus placebo on sleep systolic blood pressure (SBP) by ambulatory blood pressure monitoring (ABPM).
Change: sleep SBP value at 2 weeks minus value at baseline</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Systolic Blood Pressure</title>
          <description>To compare the efficacy of suvorexant versus placebo on sleep systolic blood pressure (SBP) by ambulatory blood pressure monitoring (ABPM).
Change: sleep SBP value at 2 weeks minus value at baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.7"/>
                    <measurement group_id="O2" value="-4.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Systolic Blood Pressure Variability</title>
        <description>To compare the efficacy of suvorexant versus placebo on morning SBP variability by ABPM Variability: SD Change: value at 2 weeks minus value at baseline</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Systolic Blood Pressure Variability</title>
          <description>To compare the efficacy of suvorexant versus placebo on morning SBP variability by ABPM Variability: SD Change: value at 2 weeks minus value at baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.5"/>
                    <measurement group_id="O2" value="0.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Total Sleep Time</title>
        <description>Total sleep time was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Total Sleep Time</title>
          <description>Total sleep time was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.24"/>
                    <measurement group_id="O2" value="0.43" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Time to Sleep Onset</title>
        <description>Time to sleep onset was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Time to Sleep Onset</title>
          <description>Time to sleep onset was assessed using a sleep diary. Value at week 2 - Value at week 0</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.18"/>
                    <measurement group_id="O2" value="-0.42" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nighttime SBP in Patients Achieved High Sleep Satisfaction</title>
        <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2 weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
        <time_frame>2 weeks</time_frame>
        <population>Patients who were satisfied with sleep as of 2 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nighttime SBP in Patients Achieved High Sleep Satisfaction</title>
          <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2 weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
          <population>Patients who were satisfied with sleep as of 2 weeks</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="3.5"/>
                    <measurement group_id="O2" value="3.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Albumin-to-creatinine Ratio (UACR)</title>
        <description>Percentage change in UACR from baseline to 2 weeks</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Albumin-to-creatinine Ratio (UACR)</title>
          <description>Percentage change in UACR from baseline to 2 weeks</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-15.18" upper_limit="21.45"/>
                    <measurement group_id="O2" value="-13.12" lower_limit="-27.22" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nighttime SBP in Patients Achieved Low Sleep Satisfaction</title>
        <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
        <time_frame>2 weeks</time_frame>
        <population>Patients who were not satisfied with sleep as of 2 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nighttime SBP in Patients Achieved Low Sleep Satisfaction</title>
          <description>nighttime BPs are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep) at 2weeks.
Patients are divided by sleep satisfaction and compared nighttime SBP change (value at 2 weeks minus value at baseline).</description>
          <population>Patients who were not satisfied with sleep as of 2 weeks</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.9"/>
                    <measurement group_id="O2" value="-9.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NT-proBNP</title>
        <description>Percentage change in NT-proBNP from baseline to 2 weeks</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NT-proBNP</title>
          <description>Percentage change in NT-proBNP from baseline to 2 weeks</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" lower_limit="-13.90" upper_limit="24.77"/>
                    <measurement group_id="O2" value="-2.80" lower_limit="-19.06" upper_limit="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suvorexant</title>
          <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
suvorexant: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
Placebo: Placebo once daily before bedtime.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Kazuomi Kario</name_or_title>
      <organization>Jichi Medical University School of Medicine</organization>
      <phone>+81-285-58-7538</phone>
      <email>kkario@jichi.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

